Endomembrane organelle maturation requires cargo delivery via fusion with membrane transport intermediates and recycling of fusion factors to their sites of origin. Melanosomes and other lysosome-related organelles obtain cargoes from early endosomes, but the fusion machinery involved and its recycling pathway are unknown. Here, we show that the v-SNARE VAMP7 mediates fusion of melanosomes with tubular transport carriers that also carry the cargo protein TYRP1 and that require BLOC-1 for their formation. Using live-cell imaging, we identify a pathway for VAMP7 recycling from melanosomes that employs distinct tubular carriers. The recycling carriers also harbor the VAMP7-binding scaffold protein VARP and the tissue-restricted Rab GTPase RAB38. Recycling carrier formation is dependent on the RAB38 exchange factor BLOC-3. Our data suggest that VAMP7 mediates fusion of BLOC-1–dependent transport carriers with melanosomes, illuminate SNARE recycling from melanosomes as a critical BLOC-3–dependent step, and likely explain the distinct hypopigmentation phenotypes associated with BLOC-1 and BLOC-3 deficiency in Hermansky–Pudlak syndrome variants.
Introduction
Secretory and endolysosomal organelles mature by the membrane transport–dependent delivery of cargoes and removal of excess material. Cargo delivery requires sorting from a source compartment into nascent transport carriers; motility of the carriers toward the target organelle; and tethering, docking, and fusion of the carriers with the maturing target (Bonifacino and Glick, 2004). Cargo removal exploits similar processes and is particularly important to recycle fusion machinery components to the source membrane for additional rounds of cargo delivery (Bonifacino and Glick, 2004; Jahn and Scheller, 2006). Although the molecular details underlying fusion machinery cycling among early secretory pathway organelles are well developed (Cai et al., 2007; Barlowe and Miller, 2013), fusion machinery trafficking in the endosomal system is poorly characterized. This cycling is particularly critical during the maturation of lysosome-related organelles (LROs), which comprise specialized cell type–specific organelles that derive from the endosomal system but support distinct physiological functions in metazoans (Marks et al., 2013). LRO biogenesis requires dedicated and nonredundant pathways for content delivery; a similar dedicated pathway for content removal has not been described.
The importance of dedicated trafficking pathways in LRO biogenesis is underscored by Hermansky–Pudlak syndrome (HPS), a group of genetic diseases in which some LROs fail to mature properly with consequently impaired vision, skin and hair pigmentation, blood clotting, and often lung function (Wei, 2006; Wei and Li, 2013). HPS results from mutations in any of at least 10 genes that encode subunits of four cytoplasmic multisubunit protein complexes: adaptor protein-3 (AP-3) and biogenesis of lysosome-related organelles complex (BLOC) 1, 2, and 3 (Dell’Angelica, 2004; Di Pietro and Dell’Angelica, 2005). These complexes are thought to regulate membrane trafficking during LRO biogenesis, as best characterized in the maturation of melanosomes, the LROs in which melanins are synthesized and stored in pigment cells of the hair, skin, and eyes (Sitaram and Marks, 2012). AP-3, BLOC-1, and BLOC-2 affect the delivery of melanogenic enzymes, transporters, and accessory proteins from early endosomes to nonpigmented melanosome precursors via two pathways. One pathway requires BLOC-1 (Setty et al., 2007, 2008; Cullinane et al., 2011; Sitaram et al., 2012), together with the microtubule motor KIF13A and actin remodeling factors (Delevoye et al., 2009, 2016), for melanosome cargoes to exit endosomes into tubular transport carriers. BLOC-2 then targets these carriers specifically to melanosomes (Dennis et al., 2015). A second BLOC-1– and BLOC-2–independent pathway requires AP-3 for cargo sorting into melanosome-bound vesicles (Huizing et al., 2001; Theos et al., 2005; Setty et al., 2007, 2008), although AP-3 can also cooperate with BLOC-1 (Newell-Litwa et al., 2009; Sitaram et al., 2012). How BLOC-3 functions during melanosome biogenesis is not clear. BLOC-3 is a guanine nucleotide exchange factor (GEF) for the cell type–restricted Rab GTPases RAB32 and RAB38 (Gerondopoulos et al., 2012). BLOC-3 and both Rabs are implicated in the biogenesis of melanosomes and other LROs (Wasmeier et al., 2006; Lopes et al., 2007; Osanai et al., 2010; Bultema et al., 2012, 2014), but whether they function in pathways into or out of melanosomes is not known.
To deliver their contents to maturing melanosomes, endosome-derived transport carriers must fuse with the melanosome membrane. Membrane fusion within the endomembrane system is mediated by SNARE proteins (Chen and Scheller, 2001; Jahn and Scheller, 2006). Typically, engagement of v-SNAREs on transport carriers with cognate three-helix t-SNARE complexes on target membranes leads to assembly of stable four-helix bundles that destabilize the membrane and drive fusion (Domanska et al., 2010; Mohrmann et al., 2010). Several SNAREs have been implicated in melanosome biogenesis (Huang et al., 1999; Wade et al., 2001; Ghiani et al., 2010; Tamura et al., 2011; Yatsu et al., 2013; Jani et al., 2015), but among them, VAMP7 (also known as tetanus neurotoxin insensitive or TI-VAMP) is the only v-SNARE. VAMP7 facilitates fusion of late endosomes with lysosomes (Luzio et al., 2010) and with maturing secretory autophagosomes (Fader et al., 2009, 2012), as well as glycosylphosphatidylinositol-anchored protein delivery to the plasma membrane (Molino et al., 2015). An additional role for VAMP7 in melanosome maturation is suggested by its localization to melanosomes (Jani et al., 2015) and by the hypopigmentation (Jani et al., 2015) and mistrafficking of the melanosomal protein TYRP1 (Tamura et al., 2011) in VAMP7-depleted cells. Moreover, the VAMP7- and RAB32/38-interacting protein VARP is required for proper TYRP1 localization (Tamura et al., 2009) and must bind VAMP7 for this function (Tamura et al., 2011). However, it is not known whether the VAMP7 requirement is direct or in which pathway it participates. Additionally, although Hrb facilitates VAMP7 recycling from the plasma membrane after fusion with VAMP7-containing organelles (Pryor et al., 2008), a pathway for recycling VAMP7 from intracellular organelles has not been described in any cell system.
Here, we exploit quantitative live-cell imaging analyses of VAMP7 dynamics in immortalized melanocytes from mouse HPS models. We show that VAMP7 is a BLOC-1–dependent cargo that likely functions as the v-SNARE during fusion of tubular transport intermediates with maturing melanosomes. Importantly, we also describe a distinct tubular pathway to retrieve VAMP7 from melanosomes after cargo delivery and show that this pathway requires BLOC-3. Our data provide the first evidence of SNARE recycling from a LRO, provide new insights into SNARE recycling in the late endosomal system in mammalian cells, and identify a novel membrane trafficking step in melanocytes that is regulated by BLOC-3.
Results
VAMP7 localizes to melanosomes and is required for melanosome cargo trafficking and pigmentation
VAMP7 is thought to localize to melanosomes and to be required for melanogenesis (Tamura et al., 2011; Yatsu et al., 2013; Jani et al., 2015). We first confirmed the localization of VAMP7 in immortal mouse melanocytes derived from C57BL/6 mice (melan-Ink4a [wild type {WT}] or melan-a; Bennett et al., 1987; Sviderskaya et al., 2002). When expressed in WT mouse melanocytes, EGFP-tagged VAMP7 (GFP-VAMP7) localized by fluorescence microscopy (FM) extensively to pigmented melanosomes in the cell periphery (82 ± 6%; n = 13 cells), and marked pigment granules more predictably (P < 0.0001) than the melanosomal cargo protein TYRP1 (65 ± 12% overlap; n = 13 cells) with which VAMP7 partially overlapped (Fig. 1, a–c). Immuno-EM using immunogold labeling on ultrathin cryosections of transfected WT melan-a cells confirmed that GFP-VAMP7 localizes to the limiting membrane of pigmented melanosomes and adjacent vesicular structures (Fig. 1 d, arrows). To identify the specific cargo trafficking defect in VAMP7-deficient cells, we depleted VAMP7 in human MNT-1 melanoma cells by siRNA-mediated knockdown (Fig. 1 e). Consistent with previous observations by bright-field (BF) microscopy (Yatsu et al., 2013; Jani et al., 2015), analysis by standard EM showed that VAMP7-depleted MNT-1 cells harbored fewer fully pigmented stage IV melanosomes and less overall pigmentation than control siRNA-treated MNT-1 cells (Fig. 1, f–h). Quantification of immunogold labeling by immuno-EM showed that whereas TYRP1 localizes predominantly to melanosomes in control siRNA-treated MNT-1 cells, a large cohort is mislocalized to tubulovesicular endosomes adjacent to melanosomes in VAMP7-depleted cells (Fig. 1, i–k, arrowheads). These data support a role for VAMP7 in pigmentation by trafficking melanosomal cargoes such as TYRP1 from endosomes to maturing melanosomes.
VAMP7 traffics to melanosomes in BLOC-1–dependent tubular carriers
To determine whether VAMP7 traffics to melanosomes via BLOC-1–independent or –dependent pathways, we analyzed GFP-VAMP7 localization in BLOC-1–deficient (BLOC-1−/−) melanocytes relative to melanosomal cargoes and the pan-early endosomal SNARE syntaxin 13 (STX13; also known as syntaxin 12) by FM. In melanocyte cell lines (melan-pa and melan-mu) from two different BLOC-1−/− mouse models (pallid and muted), GFP-VAMP7 was retained (79 ± 7% in melan-pa; n = 53 cells) in sorting and recycling endosomes, marked by expression of mCherry-STX13 (mCh-STX13; Fig. 2, a–e, arrowheads; and Fig. S1, f–i, arrowheads; compare to WT in Fig. S1, a–e, arrows) to an even higher extent (P < 0.0001) than the BLOC-1–dependent melanosome cargo TYRP1 (66 ± 14% in melan-pa; Setty et al., 2007). Melanosomal localization of GFP-VAMP7 was restored by stable expression of the missing Pallidin or Muted subunits (melan-pa:MycPa or BLOC-1R and melan-mu:MuHA rescue) before GFP-VAMP7 expression (Fig. 2, f–j; and Fig. S1, j–m). VAMP7 mislocalization in BLOC-1−/− cells does not reflect global VAMP mistrafficking, as localization of VAMP2, VAMP4, and VAMP8 was unaffected in BLOC-1−/− cells compared with WT melanocytes (Fig. 2, k–p). Together, these data suggest that VAMP7 is a BLOC-1–dependent melanosome cargo.
To test whether VAMP7 is targeted to melanosomes in BLOC-1–dependent tubular carriers, we exploited the endosomal retention of VAMP7 in BLOC-1−/− cells. BLOC-1–dependent cargo trafficking in real time is difficult to study in WT melanocytes, as cargoes such as TYRP1 are localized largely to mature pigmented melanosomes at steady state (Orlow et al., 1993; Vijayasaradhi et al., 1995; Setty et al., 2007) and thus the fraction of TYRP1 actively trafficking to melanosomes is small and difficult to detect. Because stable reexpression of Pallidin in BLOC-1−/− melan-pa melanocytes restores GFP-VAMP7 localization to melanosomes, we surmised that analysis of melan-pa cells soon after transient expression of Pallidin might allow us to visualize early BLOC-1–dependent transport events. We thus cotransfected melan-pa cells with myc-Pallidin, GFP-VAMP7, and mCh-STX13 and analyzed fixed cells by FM at various times after transfection (Fig. 2, q–v). We observed a time-dependent decrease in the extensive overlap between GFP-VAMP7 and mCh-STX13 in endosomes (arrowheads) and a concomitant increase in GFP-VAMP7–labeled structures that lacked mCh-STX13 (arrows). This GFP-VAMP7 redistribution required BLOC-1 function, as it was not observed upon cotransfection of Pallidin-deficient melan-pa cells with an excess of the Muted subunit (Fig. 2, q, u, and v; and Fig. 3, a–d and m–p), which does not restore BLOC-1 expression (Setty et al., 2007). The GFP-VAMP7–containing, mCh-STX13–negative structures were newly generated maturing melanosomes that had not yet accumulated pigment, because they contained TYRP1 (Fig. 3, e–l, arrows) and the early-stage melanosome marker PMEL (Fig. 3, q–t, arrows).
Like the early endosomes from which they derive, the BLOC-1–dependent tubular carriers through which cargoes such as TYRP1 are transferred to melanosomes, but not melanosomes themselves, were labeled by GFP- or mCh-STX13 (Setty et al., 2007; Delevoye et al., 2009, 2016; Dennis et al., 2015). To test whether VAMP7 is transported through these carriers, we analyzed melan-pa melanocytes 20 h after cotransfection with myc-Pallidin, GFP-VAMP7, and mCh-STX13. In such transiently rescued BLOC-1−/− cells, unlike in WT or stably rescued BLOC-1R cells in which mCh-STX13 is largely segregated from GFP-VAMP7 and TYRP1-GFP (Fig. 4, a–f; Fig. S2, a and b; and Videos 1 and 2), tubules emerging from mCh-STX13-labeled endosomes that contain both mCh-STX13 and either GFP-VAMP7 (Fig. 4, g–j, arrows; and Video 3) or TYRP1-GFP (Fig. 4, k–n, arrows; and Video 4) were readily visualized. In contrast, in control mock rescued cells expressing Muted-HA, STX13 tubule formation was dramatically impaired (as quantified in Delevoye et al., 2016) and GFP-VAMP7 was retained in mCh-STX13–positive vacuolar endosomes (Fig. S2, c–f, arrowheads; and Video 5). These data provide direct evidence that both melanosomal cargoes and VAMP7 traffic from early endosomes to melanosomes via STX13-containing tubules. Given the role of VAMP7 in TYRP1 delivery to melanosomes (Fig. 1), we conclude that VAMP7 likely functions in fusion of BLOC-1–dependent endosomal carriers with maturing melanosomes.
VAMP7 recycles from melanosomes in tubular carriers that lack STX13
If VAMP7 functions as a canonical v-SNARE in the fusion of endosomal transport carriers with maturing melanosomes, it must be retrieved from melanosomes for use in future rounds of cargo delivery. Consistently, we observed GFP-VAMP7–labeled structures emanating from pigmented melanosomes by live-cell fluorescence and BF microscopy of WT melanocytes (Figs. 5, a–c; Fig. S2 i; and Video 6). The GFP-VAMP7–labeled tubules (arrows) were distinct from the anterograde mCh-STX13–labeled tubules (arrowheads) that deliver cargo to melanosomes, as assessed by dual-color imaging (Fig. 5, d–g; and Video 1). This subpopulation of GFP-VAMP7–positive, melanosome–derived tubules were independent of, and shorter in length and less stable than, those labeled solely by mCh-STX13 (P < 0.0001, n = 50 tubules each; Fig. S2, g and h). The GFP-VAMP7 tubules that exit melanosomes did not contain detectable mRFP-tagged OCA2 or TYRP1 (Fig. 5, h–j; Fig. S2, k–n; and Videos 7 and 8), suggesting that they were selective for cargo destined for removal from melanosomes. Thus, GFP-VAMP7 labels membrane transport carriers that emerge from maturing melanosomes with characteristics of those that recycle SNAREs (Bonifacino and Glick, 2004; Jahn and Scheller, 2006).
VARP is associated with VAMP7 recycling tubules and is recruited to melanosomes by RAB38 and VAMP7
VAMP7 contains an autoinhibitory longin domain that can block VAMP7 interactions with cognate SNAREs (Martinez-Arca et al., 2003). The scaffolding protein VARP binds both the longin and SNARE domains of VAMP7 (Burgo et al., 2009), keeping VAMP7 in an autoinhibited conformation and impeding its fusogenic activity (Schäfer et al., 2012). VARP was proposed to support melanosome biogenesis via its ability to bind to VAMP7 (Tamura et al., 2009) and to mediate endosomal recycling in non-LRO–containing cells (Hesketh et al., 2014). Thus, we tested whether VARP associates with VAMP7 retrieved from melanosomes. When expressed in WT melanocytes, GFP- or HA-tagged VARP localized in part (30% ± 6%) to puncta adjacent to melanosomes in the cell periphery (Fig. 6, a–f), and in part (70% ± 6%) to endosomal structures, as in nonmelanocytic cells (Hesketh et al., 2014), that predominated in the perinuclear region (Fig. 6, g–i). By spinning-disk microscopy analysis of WT melanocytes, VARP-GFP was detected on nearly all mCh-VAMP7 tubulovesicular structures (arrows) that exited from melanosomes (arrowhead) in the cell periphery (Figs. 6, j–l; Fig. S3 a; and Video 9). Like the VAMP7-labeled tubules, VARP-GFP–labeled tubules were not enriched for the melanosomal cargoes TYRP-mRFP or mRFP-OCA2 (Figs. 6, m–o; Fig. S3, b and e–h; and Videos 10 and 11). These results place VARP on the VAMP7-containing tubules that exit melanosomes, where VARP might stabilize VAMP7 in a nonfusogenic state. VARP-GFP–labeled tubules also extended from mCh-STX13–labeled endosomes in the perinuclear region (Fig. 6, p–r; Fig. S3 c; and Video 12), but they were distinct from the STX13-labeled tubules that traffic cargo to melanosomes (Fig. 6, s–u; Fig. S3 d; and Video 12) and likely represent carriers that recycle cargoes such as GLUT-1 to the cell surface (Hesketh et al., 2014) or that mediate retrograde endosome to TGN trafficking (Wassmer et al., 2009).
In addition to VAMP7, VARP binds to RAB32/38 and the VPS29/35 subunits of the retromer complex via distinct sites (Zhang et al., 2006; Wang et al., 2008; Burgo et al., 2009; Tamura et al., 2009; Hesketh et al., 2014; McGough et al., 2014) and functions as a RAB21 GEF (Zhang et al., 2006). In nonmelanocytic cells, retromer binding is required to recruit VARP to endosome-derived tubules, and both retromer and VARP participate in GLUT-1 trafficking to the cell surface (Hesketh et al., 2014; McGough et al., 2014). In melanocytes, TYRP1 localization to melanosomes requires both retromer (McGough et al., 2014) and VARP binding to VAMP7 and RAB32/38, but not RAB21 GEF activity (Tamura et al., 2011). Like VAMP7, RAB38 and RAB32 localize in part to melanosomes (Wasmeier et al., 2006; Bultema et al., 2012; Gerondopoulos et al., 2012). Indeed, GFP-RAB38 overlapped by FM with VARP-HA on puncta adjacent to melanosomes (Fig. 7, a–h) and, like VARP, GFP-RAB38 was detected on mCh-VAMP7–containing tubules that exit melanosomes (Fig. 7, i–l; and Video 13). Therefore, we investigated the requirement for VAMP7, RAB32/38, and retromer in recruiting VARP to melanosomes by exploiting VARP site-directed mutants in which binding to each partner is impaired (Hesketh et al., 2014). We expressed GFP-tagged full-length VARP or site-directed mutants in WT melanocytes and quantified GFP-positive puncta that associated with pigmented melanosomes (arrowheads) or with mCh-STX13–labeled endosomes (Fig. 8, a–g, arrows). Mutagenesis of either the VAMP7 or the RAB32/38 binding site resulted in decreased VARP localization to melanosomes by 57% ± 18% or 60% ± 19%, respectively, and loss of both binding sites led to a further reduction (87% ± 11% less than WT). However, as in nonpigmented cells (Hesketh et al., 2014), these mutations had no effect on VARP association with mCh-STX13–labeled early endosomes. In contrast, mutagenesis of the retromer binding site had no effect on melanosome localization but severely impaired the association of VARP with mCh-STX13 endosomes as in nonmelanocytic cells (Hesketh et al., 2014). Thus, VARP recruitment to pigmented melanosomes depends primarily on interactions with both VAMP7 and RAB32/38, with which it associates in retrograde transport carriers, and does not require binding to retromer.
BLOC-3 is required for RAB38 and VARP recruitment to melanosomes and facilitates formation of VAMP7 recycling tubules
BLOC-3, composed of HPS1 and HPS4 subunits that are defective in the majority of HPS patients (Seward and Gahl, 2013), is a GEF for RAB32 and RAB38 (Gerondopoulos et al., 2012), but the effects of BLOC-3 mutations on melanosome biogenesis are unclear and vary in different pigment cell types (Gardner et al., 1997; Nguyen et al., 2002; Richmond et al., 2005; Nguyen and Wei, 2007; Gerondopoulos et al., 2012). Like BLOC-3–deficient hair bulb melanocytes (Nguyen et al., 2002) and primary mouse melanocytes (Gardner et al., 1997), immortal BLOC-3–deficient melan-le (from HPS4-deficient light ear mice) and melan-ep (from HPS1-deficient pale ear mice) melanocytes harbor abundant pigmented melanosomes, some of which are unusually large (Fig. 9, c, l, and u; Fig. S4, g, k, and o; and Fig. S5, c, k, o, and w). The extent of TYRP1 localization to pigment granules in these cells was only slightly reduced relative to WT melanocytes (Fig. 9, a–h; and Fig. S4, a–d; 66% ± 6% of TYRP1 overlapped with pigment granules in WT melan-a cells, 56% ± 8% in melan-le; difference is not statistically significant); similarly, segregation of the lysosomal membrane protein LAMP2 from pigment granules was only slightly impaired (Fig. 9, a–h; and Fig. S4, a–d; 5% ± 3% of LAMP2 overlapped with pigment granules in WT melan-a cells, 14% ± 5% in melan-le; P = 0.003). These data indicate that BLOC-3 is not directly responsible for anterograde cargo trafficking to melanosomes or for gross melanosome segregation from the endolysosomal system. We thus tested whether BLOC-3 deficiency affected RAB38 and VARP localization and VAMP7 recycling. Consistent with BLOC-3 function as a RAB38 GEF, GFP-RAB38 in HPS4-deficient melan-le cells was largely diffuse and did not associate with pigment granules (Fig. 9, i–m). Accordingly, VARP localization to melanosomes was also substantially reduced in melan-le cells (Fig. 9, s–v). Stable reexpression of a WT HPS4 subunit in HPS4-deficient melan-le melanocytes, but not of excess WT HPS1, restored both RAB38 and VARP melanosomal localization to WT levels (Fig. 9, n–r and w–z; and Fig. S4, i–p). Similar data were obtained using HPS1-deficient melan-ep melanocytes and stable reexpression of “rescuing” HPS1 or “nonrescuing” HPS4 (Fig. S5, a–x). Thus, BLOC-3 activation is required for the recruitment and/or stabilization of RAB38 on/to melanosomes and for subsequent effective VARP recruitment.
To test whether BLOC-3 is required for VAMP7 recycling, we quantified the fission of GFP-VAMP7–containing tubules from melanosomes by live imaging of transiently transfected WT melanocytes, HPS4-deficient melan-le (le), or melan-le cells stably expressing either HPS1 (le:HPS1) or HPS4 (le:HPS4). As in WT melanocytes, the majority of GFP-VAMP7 (78% ± 9%, n = 23 cells; not significantly different from WT) localized to melanosomes in the periphery of melan-le cells (Fig. 9 j). However, whereas GFP-VAMP7–labeled tubules were frequently observed emanating from these structures in WT cells (Fig. 10, a and d; and Video 14), such tubules were rare in melan-le cells (Fig. 10, b and d). Restoration of BLOC-3 function by stable expression of HPS4 restored WT tubule frequency, whereas stable expression of HPS1 did not (Fig. 10, c and d). Thus, BLOC-3 regulates recycling of VAMP7 from melanosomes, most likely by recruiting RAB38 and consequently VARP to initiate and/or complete tubule formation.
Discussion
VAMP7 has been implicated in melanosome biogenesis (Tamura et al., 2011; Jani et al., 2015), but the pathways by which it is directed toward and recycled from melanosomes were unknown. Here, we show that VAMP7 functions during melanosome biogenesis primarily as a v-SNARE in BLOC-1–dependent tubular transport from endosomes to melanosomes and thereby promotes melanosomal delivery of BLOC-1–dependent cargoes such as TYRP1. Importantly, our analyses of VAMP7 dynamics revealed a previously undocumented SNARE retrieval pathway from maturing melanosomes. This pathway employs membrane tubules that emerge from melanosomes at sites enriched in RAB38 and VARP and that require the RAB32/38 GEF BLOC-3 for their formation. The resulting model (Fig. 10 e) has important implications for RAB32/38, BLOC-3, and VAMP7 function in the biogenesis of other LROs and in the etiology of the most common forms of HPS.
Cargoes are delivered to melanosomes by two distinct pathways that emerge from early endosomes: one that requires BLOC-1 and a second that is BLOC-1 independent (Sitaram and Marks, 2012). Our data using a novel transient rescue assay place VAMP7 on the BLOC-1–dependent pathway that also delivers melanosomal cargoes such as TYRP1 and OCA2. That VAMP7 is a cargo of the BLOC-1 pathway is consistent with the reduced VAMP7 levels in lysates of BLOC-1–deficient fibroblasts and 293T cells and in synaptic vesicle fractions of BLOC-1–deficient neurons (Salazar et al., 2006; Ryder et al., 2013). The altered TYRP1 distribution in cells depleted of VAMP7 indicates that VAMP7 likely functions as the main v-SNARE for cargo delivery in this pathway. Given that STX13 labels the BLOC-1–dependent transport intermediates (Dennis et al., 2015), this function for VAMP7 likely explains the reported requirement for VAMP7 in the accumulation of truncated STX13 on melanosomes (Jani et al., 2015). VAMP7 might similarly facilitate fusion of tubular intermediates between endosomes and lysosomes in cell types that lack LROs (Bright et al., 2005); formation of such tubules, like a subclass of recycling endosomes (Delevoye et al., 2016), might require BLOC-1 or the structurally related BORC (Pu et al., 2015).
v-SNAREs are thought to cycle back to their membrane of origin after cargo delivery to mediate additional rounds of cargo trafficking (Bonifacino and Glick, 2004; Jahn and Scheller, 2006). However, to our knowledge, the only described pathway for v-SNARE retrieval in the late endosomal system in mammalian cells is the Hrb-dependent recycling of VAMP7 from the plasma membrane after fusion with late endosomes (Pryor et al., 2008). Here, we visualized the retrieval of VAMP7 from melanosomes in small tubular intermediates. Melanosomal cargoes were not enriched in these tubules, indicating that the tubules are cargo selective. VARP association with these tubules implies that VAMP7 within them is bound to VARP and thus inactive (Schäfer et al., 2012), as expected for a recycling v-SNARE. We speculate that VARP is released before fusion with the target, allowing VAMP7 to serve as a v-SNARE during recycling. We could not visualize the target compartment of these rapidly motile tubules by single-plane spinning-disc microscopy, but we speculate that they ultimately return VAMP7 to STX13-containing early endosomes either directly or via late endosomes or the plasma membrane. It is also unclear how cargo is selected for entry into the tubules but AP-3, which engages VAMP7 on early endosomes (Martinez-Arca et al., 2003; Kent et al., 2012) and was recently suggested to facilitate STX13 recycling from melanosomes (Jani et al., 2015), is unlikely to participate in this process, as VAMP7 is localized normally in AP-3–deficient melanocytes (unpublished data). VARP itself might sort VAMP7 into the tubules; testing this model will require reconstitution of VARP-deficient melanocytes with specific binding mutants.
The dramatic depletion of VAMP7-containing recycling tubules in cells lacking BLOC-3 suggests that RAB38 and/or RAB32 play an important role in recruiting effectors for cargo selection, tubule formation, and/or tubule release. One such effector might be the RAB32/38 binding partner myosin Vc (Bultema et al., 2014), which might primarily mediate recycling tubule dynamics with secondary effects on melanosome secretion (Bultema et al., 2014). RAB38 and VAMP7 might indirectly engage other recycling effectors via VARP, akin to the recruitment of the kinesin-1 motor KIF5 by VARP in neurons (Burgo et al., 2012). The ubiquitously expressed BLOC-3 (Chiang et al., 2003; Martina et al., 2003; Nazarian et al., 2003) might facilitate VAMP7 retrieval from other organelles in cell types that lack LROs, perhaps through activation of trace levels of RAB32 or RAB38 or of a distinct RAB. Note that although binding to retromer was not required for VARP recruitment to melanosomes, our data do not negate a role for retromer in either anterograde or retrograde transport as recently proposed (McGough et al., 2014).
Although BLOC-3 clearly functions as a GEF for RAB32 and RAB38 (Gerondopoulos et al., 2012), the physiological roles of BLOC-3 and its target RABs during melanosome biogenesis were unknown. Simultaneous depletion of RAB32 and RAB38 (Loftus et al., 2002; Wasmeier et al., 2006; Bultema et al., 2012) or VARP (Tamura et al., 2009, 2011) in skin melanocytes resulted in pigment dilution and TYR and TYRP1 mislocalization largely to the Golgi and/or TGN. Similarly, retinal pigment epithelia (RPE) from RAB38-deficient chocolate mice are depleted of melanosomes and mislocalize a cohort of TYR (Lopes et al., 2007), and MNT-1 melanoma cells depleted of RAB32, RAB38, or BLOC-3 subunits are severely hypopigmented (Gerondopoulos et al., 2012). These data were interpreted as a direct role for these proteins in anterograde traffic, but they could also be explained by an indirect role through a failure of VAMP7 recycling and its resulting entrapment on melanosomes; this would deplete VAMP7 from early endosomes with a consequent secondary failure in anterograde trafficking, as seen with VAMP7 knockdown (Tamura et al., 2011; Jani et al., 2015; Fig. 1). This model for a primary role for BLOC-3 and RAB38 in retrograde transport would be consistent with the localization of RAB32 and RAB38 primarily to melanosomes (Bultema et al., 2012; Gerondopoulos et al., 2012; Fig. 7, a–h) and secondarily to tubulovesicular membranes (Wasmeier et al., 2006) that might be retrograde, rather than anterograde, transport intermediates. The reported interactions of RAB38 and RAB32 with the anterograde trafficking factors AP-1, BLOC-1, and BLOC-2 (Bultema et al., 2012) might coordinate anterograde and retrograde trafficking.
Intriguingly, a primary role for BLOC-3 and RAB32/38 in VAMP7 recycling could also explain the variable phenotypes of pigment cells in BLOC-3–deficient mice (Gardner et al., 1997; Nguyen and Wei, 2007) and HPS patients (Anderson et al., 2003; Takeuchi et al., 2014). In eyes of BLOC-3–deficient light ear or pale ear mice, RPE harbor few small, lightly pigmented melanosomes, whereas melanocytes of the adjacent choroid contain highly pigmented macromelanosomes (Gardner et al., 1997; Suzuki et al., 2002). Similarly, light ear and pale ear hair bulb melanocytes (like the immortalized melan-ep and melan-le cells used here) harbor enlarged but otherwise normally pigmented melanosomes (Nguyen et al., 2002), whereas interfollicular skin melanocytes (like BLOC-3–depleted MNT-1 cells [Gerondopoulos et al., 2012] and HPS1 patient primary melanocytes [Boissy et al., 1998]) harbor fewer, small, hypopigmented melanosomes (Nguyen and Wei, 2007); these differences result in dark fur and light skin (Lane and Green, 1967). We speculate that these cell type–specific differences in melanosome biogenesis reflect different requirements for VAMP7 recycling in maintaining an endosomal pool of VAMP7 for anterograde transport. For example, cell types with low levels of VAMP7 expression and/or high rates of melanosome biogenesis would deplete VAMP7 from endosomes and hence block anterograde cargo trafficking required for melanosome maturation, resulting in fewer, smaller and hypopigmented melanosomes. Alternatively, cell types with high levels of VAMP7 expression and/or low rates of melanosome biogenesis might restore sufficient levels of endosomal VAMP7 biosynthetically to compensate for the loss of recycling and permit sufficient anterograde cargo delivery for melanosome synthesis. The enlarged melanosomes in such cells would result from (1) continued anterograde membrane delivery without compensating retrograde membrane retrieval and (2) fusion of melanosomes with each other and with other organelles because of an excess of “unprotected” fusogenic VAMP7 lacking VARP. A similar rationale might explain the differences in melanosome biogenesis in the RPE and choroidal melanocytes in RAB38-deficient chocolate mice (Brooks et al., 2007; Lopes et al., 2007) and, perhaps, the defect in TYRP1 localization in VARP-depleted melan-a cells (Tamura et al., 2009, 2011). Although future analyses of the rates of melanosome biogenesis and VAMP7 biosynthesis will be necessary to test these models, the identification of a VAMP7 recycling pathway from melanosomes that is regulated by BLOC-3 provides a new way of thinking about an old problem.
Materials and methods
Reagents
Chemicals were obtained from Sigma-Aldrich, except where noted. Hygromycin B was obtained from Roche. Tissue culture reagents and Lipofectamine 2000 were obtained from Invitrogen. Matrigel was obtained from BD.
Cell culture and generation of stable cells
Immortalized melanocyte cell lines melan-Ink4a-1 (also known as melan-Ink-4a-Arf-1; referred to here as melan-Ink4a or WT) derived from C57BL/6 Ink4a-Arf−/− mice (Sviderskaya et al., 2002), melan-ep1 (referred to here as melan-ep) derived from BLOC-3–deficient C57BL/6J Hps1ep/ep pale ear mice and melan-le1 (referred to here as melan-le) derived from BLOC-3–deficient C57BL/6J Hps4le/le light ear mice (Suzuki et al., 2002; Chiang et al., 2003), and melan-pa1 (referred to here as melan-pa) derived from BLOC-1–deficient C57BL/6J-Pldnpa/pa pallid mice, melan-mu1 (referred to here as melan-mu) derived from BLOC-1–deficient B6.CHMU/Le Mutedmu/mu muted mice, and stably transduced melan-pa:myc-Pa and melan-mu:MuHA lines in which BLOC-1 function is restored via expression of the missing subunit (Setty et al., 2007) have been previously described. All cells were cultured in RPMI 1640 medium supplemented with 10% FBS (Atlanta Biologicals) and 200 nM 12-O-tetradecanoylphorbol-13-acetate. Melan-le, melan-ep, and stable lines derived from these cells were also cultured in the presence of 200 pM cholera toxin. Stably transduced cell lines were generated by infection with recombinant retroviruses produced in transiently transfected Plat-E cells (Morita et al., 2000) and selection with 100 µg/ml (for melan-ep based lines) or 150 µg/ml (for melan-le based lines) hygromycin B as described previously (Setty et al., 2007; Meng et al., 2012). Stable cell lines were occasionally treated with hygromycin B (100 or 150 µg/ml) to maintain selection for transgene expression. In most experiments, cells were transiently transfected with expression plasmids using Lipofectamine 2000 (1 µl with 800 ng DNA, including carrier DNA as needed, in 100 µl Opti-MEM for each coverslip in a 24-well plate or 4 µl Lipofectamine 2000 with 4 µg DNA in 500 µl Opti-MEM for 35-mm glass-bottom dishes) and imaged at varying times after transfection as indicated. Only cells with low or modest levels of transgene expression were chosen for analysis, and DNA amounts were titrated to ensure modest but detectable expression in 10–40% of transfected cells.
Antibodies
The following monoclonal antibodies were used: mouse anti-TYRP1 (TA99) from ATCC; rat anti-LAMP1 (1D4B) and rat anti-LAMP2 (GL2A7) from Developmental Studies Hybridoma Bank; mouse anti-PMEL (HMB-45) from Lab Vision; and mouse anti-HA.11 from Covance. Anti-VAMP7 mAb (158.2) and pAb (TG50) have previously been described and validated using Vamp7−/− mice (Danglot et al., 2012). Polyclonal rabbit antisera to STX13 (Prekeris et al., 1998) have been previously described, and rabbit anti-Giantin was purchased from Abcam (ab24586). Species-specific secondary antibodies from donkey conjugated to Alexa Fluor 488, 594, or 647 or Dylite 488, 594, or 647 used in immuno-FM were obtained from Jackson ImmunoResearch Laboratories, Inc.
DNA constructs and siRNAs
The siRNAs used were human VAMP7 siRNA (5′-CTGCCAAGACAGGATTGTATA-3′; Danglot et al., 2010) and control siRNA (5′-AATTCTCCGAACGTGTCACGT-3′). Recombinant retroviral vectors pBMN-X/N-IRES-Hygro-HA3-hHPS1 and pBMN-X/N-IRES-Hygro-HA3-hHPS4 encoding human HPS1 and HPS4 under the control of the Maloney mouse leukemia virus promoter were generated by subcloning the XhoI–NotI cDNA fragment from pCI-HA3-humanHPS1 and pCI-HA3-humanHPS4 (gifts from J. Bonifacino, National Institutes of Health, Bethesda, MD) into pBMN-X/N-IRES-Hygro. pCR3-mRFP-OCA2, pmCh-C1-STX13, pEGFP-C1-STX13, and pEGFP-N1-TYRP-EGFP (Dennis et al., 2015); pBMN-IRES-Hygro-mycPa and pBMN-IRES-Hygro-mycMu (Setty et al., 2007); pLXIN-huVARP-HA2 (Schäfer et al., 2012); and pLXIN-huVARP-EGFP, pLXIN-huVARP(M684D,Y687S)-EGFP, pLXIN, huVARP(Q509A,Y550A)-EGFP, pLXIN-huVARP(H432S,L434A,H712S,L714A)-EGFP, and pEGFP-N1-VARP(WT)-EGFP (Hesketh et al., 2014) have been previously described. pmRFP-N1-TYRP-mRFP was generated by amplifying mRFP from pmRFP-N1 by PCR and subcloning the resulting SalI–NotI fragment into pEGFP-N1-huTYRP1. pEGFP-C2-RAB38 was a gift from A. Hume (University of Nottingham, Nottingham, England, UK). mCh-RAB38 controlled by the cytomegalovirus immediate early (CMV) promoter was generated by subcloning mCh into pEGFP-C2-RAB38 using the AgeI–XhoI region of mCh from pmCh-C1 (Takara Bio Inc.). pLXIN-VAMP4-HA (Gordon et al., 2009) was a gift from A. Peden (University of Sheffield, Sheffield, England, UK). EGFP-VAMP2, EGFP-VAMP7, and EGFP-VAMP8 in pEGFP-C vector, controlled by the CMV promoter and generated from rat cDNA, were gifts from P. Roche (National Institutes of Health, Bethesda, MD). pmCh-VAMP7 controlled by the CMV promoter was generated by subcloning mCh into pEGFP-C-VAMP7 using the AgeI–BsrGI region of mCh from pmCh-C1 (Takara Bio Inc.).
EM
For conventional EM, MNT-1 cells were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer (1.5 h on ice), postfixed with 1% OsO4/1.5% potassium ferricyanide (45 min on ice), dehydrated in ethanol, and embedded in epon resin. For ultrathin cryosectioning, MNT-1 cells fixed with 2% PFA and 0.2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) were processed for ultracryomicrotomy and immunogold labeled using TYRP1 antibody (TA99) followed by protein A conjugated to 10 nm gold (PAG10). Electron micrographs were acquired using Philips CM120 or Tecnai Spirit G2 (FEI) equipped with a numeric camera (Keen View; Soft Imaging System) or 4k charge coupled device camera (Quemesa; Olympus).
Immunoblotting
MNT-1 cells were seeded at 106 per 10-cm Petri dish and transfected with Oligofectamine (Invitrogen) 2 d later with control- or VAMP7-specific siRNAs and then again after an additional 3 d. 3 d later, cells were washed in cold PBS and incubated in cold lysis buffer (50 mM Tris, 150 mM NaCl, 0.1% Triton X-100, and 10 mM EDTA, pH 7.2, supplemented with protease inhibitor cocktail [Roche]) for 20 min on ice. Cell lysates were collected by scraping and clarified by centrifugation for 15 min at 13,000 rpm (4°C). Lysates were incubated with sample buffer (2× concentrated), boiled for 5 min, and processed for immunoblotting.
Quantification of melanin content
MNT-1 cells were seeded at 105 per well in a six-well plate and transfected twice with siRNA as for immunoblotting. 3 d after the second siRNA transfection, cells were washed twice in cold PBS and incubated with 200 µl cold melanin buffer (50 mM Tris, 150 mM NaCl, and 2 mM EDTA, pH 7.2). Cells were scraped and sonicated, and 100 µl lysate was centrifuged at 13,000 rpm for 15 min at 4°C. Supernatants were removed and pellets washed with 500 µl ethanol/ether (1:1 ratio) and dissolved in 230 µl 2 M NaOH/20% DMSO for 1 h at 60°C. The optical density at 490 nm of 200 µl of solubilized melanin was measured and normalized to protein content evaluated by Bradford assay (Thermo Fisher Scientific).
FM
Standard immuno-FM and colocalization analyses
Cells were plated on Matrigel-coated coverslips, fixed with 3% PFA in Hank’s buffered salt solution, labeled with primary and secondary antibodies and mounted using Vectashield H-1000 (Vector Laboratories). Cells were analyzed by epifluorescence microscopy on a DM IRBE or DMI 6000B microscope (Leica Biosystems) equipped with a 63× Plan Apochromat objective (1.4 NA) and either a Retiga EXi Fast 1394 or a Hamamatsu Photonics ORCA-Flash4.0 sCMOS digital camera. Images were acquired in z-stacks using a 0.2-µm (DM IRBE) or 0.19-µm (DMI 6000B) step size and deconvolved using either subtractive volume deconvolution with OpenLab (PerkinElmer) software or Gold’s Method deconvolution with three iterations in LASX (Leica Biosystems) software.
Quantification of overlap between markers in melanosomes
Quantification of the area of overlap in the cell periphery between two fluorescent labels or a fluorescent label and pigmented melanosomes was performed using ImageJ (National Institutes of Health) on wide-field fluorescence images using a method similar to that previously used with OpenLab software (Setty et al., 2007). In brief, images were cropped to contain a single cell with the nucleus and perinuclear area removed, and binary images of fluorescence were generated by subtracting the local background before thresholding using parameters of a rolling ball radius of 10 pixels with smoothing disabled. Binary images of pigment granules from BF imaging were generated by manual thresholding. The Image Calculator function was used to generate an image representing the area of overlap between channels by multiplying the binary images for each of the two channels. The areas of overlap and of total fluorescent labeling in structures larger than five pixels were quantified using the Analyze Particles function; the ratio of overlap pixels to total fluorescent pixels in the channel of interest gives the percentage of overlap.
Transient rescue of BLOC-1− cells expressing GFP-VAMP7, TYRP-GFP, and mCh-STX13
BLOC-1−/− melan-pa cells were seeded on Matrigel-coated coverslips in 24-well tissue culture plates and 24 h later transiently transfected with Lipofectamine using 200 ng each of pEGFP-C-VAMP7 and pmCh-C1-STX13 and 500 ng of either pBMN-IRES-Hygro-mycMu or pBMN-IRES-Hygro-mycPa. At indicated times after transfection, cells were fixed with 3% PFA in Hank’s buffered salt solution and either mounted directly using Vectashield or processed for standard immuno-FM as described above with either TA99 or HMB-45 and Dylite647-conjugated secondary antibodies. Cells were imaged as for standard immuno-FM. The number of GFP-VAMP7-positive, mCH-STX13-negative puncta was quantified by manual counting within selected 200 × 200–pixel regions in the periphery of cells. Quantification of overlap between GFP-VAMP7 and mCh-STX13 in the cell periphery was completed as described above for Standard immuno-FM and colocalization analyses.
Quantification of melanosomal and endosomal VARP localization using site-directed VARP mutants
WT melan-Ink4a melanocytes were seeded on Matrigel-coated coverslips and transfected using Lipofectamine 2000 with mCh-STX13 and either pLXIN-VARP(WT)-EGFP or the site-directed pLXIN-VARP-GFP mutants deficient for binding to VAMP7 only, RAB38 only, both VAMP7 and RAB38, or retromer. 48 h after transfection, cells were fixed and processed for standard immuno-FM and deconvolved using LASX and Gold’s method (three iterations). Quantification of VARP-GFP puncta associated with melanosomes visualized by BF microscopy or associated with mCh-STX13–labeled endosomes was done by manual counting after excluding a 200-pixel-diameter circular selection containing the nucleus and Golgi region.
Live-cell imaging
Cells were seeded in Matrigel-coated 35-mm glass-bottom dishes and transiently transfected with indicated GFP- or mCh/mRFP-fusion proteins using Lipofectamine 2000. At indicated times after transfection, cells in riboflavin-free RPMI (US Biological) containing 10% FBS were imaged on a Axiovert 200 microscope (ZEISS) equipped with a 63X Plan-Apo objective lens (NA 1.4), an UltraVIEW ERS6 spinning-disk confocal scan head (PerkinElmer), an environmental chamber at 37°C, an Orca ER CCD camera (Hamamatsu Photonics) and Volocity (PerkinElmer) software for image acquisition. In some experiments, an ORCA-Flash4.0 sCMOS camera was used instead. For imaging of cells expressing GFP-VAMP7 relative to melanosomes imaged by BF microscopy (Fig. 5, a–c; and Fig. S2 i), we used an Olympus IX71 spinning-disk confocal microscope equipped with a 100× Plan-Apo objective (NA 1.4), LCI Chamlide stagetop incubation chamber at 37°C/5% CO2, an ImageEM EM-CCD camera (Hamamatsu Photonics), and MetaMorph (Molecular Devices) software for image acquisition. Image sequences were further analyzed using ImageJ. All images were captured at ∼1 frames per second (fps) except for Video 9, which was captured at ∼1.4 fps.
Quantification of GFP-VAMP7 and mCh-STX13 tubule length and stability
To quantify the length and stability of GFP-VAMP7 and mCh-STX13 tubules in WT melan-Ink4a melanocytes, cells were seeded in Matrigel-coated 35 mm glass-bottom dishes, cotransfected with GFP-VAMP7 and mCh-STX13 and imaged 24 h later as described in the section above at ∼1 fps. Tubule length was measured by tracing the tubule at its maximum length using the “Measure” command in ImageJ, and tubule stability was measured by counting the total number of frames in which an identifiable tubule was present. 50 total tubules (five tubules from each of ten cells, acquired on at least three independent days) were quantified for each type of tubule.
Quantification of GFP-VAMP7 tubules leaving melanosomes
To quantify the number of GFP-VAMP7 tubules leaving melanosomes in WT, BLOC-3–deficient, and BLOC-3–rescued cells, cells were seeded on Matrigel-coated 35-mm glass-bottom plates, transfected with GFP-VAMP7 using Lipofectamine 2000, and imaged 24 h after transfection. Image sequences were acquired for 5 min at ∼1 fps (300 images) as described above in the Live-cell imaging section. Quantification was completed using ImageJ Fiji. First, the perinuclear region of each cell was excluded by placing a circular region of interest with diameter 200 pixels over the nucleus and adjacent Golgi region as visualized by an accumulation of GFP-VAMP7 signal. 50 × 50–pixel regions were selected and cropped from the periphery of each cell, avoiding the nuclear ROI and edges of the cell. Local background was subtracted from these 50-pixel-square regions using the “Process -> Subtract Background” command in ImageJ with settings of rolling ball radius of 10 pixels, and a sliding parabola with all other boxes unchecked; the resulting “background subtracted” file was further processed using the “Smooth” command to yield a “smoothed” file. The “Combine” command was then used to place the “background subtracted” and “smoothed” files adjacent to each other, and only fission of tubules that were observed in both files were included in the quantification. For quantification, the number of GFP-VAMP7 tubules/vesicles observed to depart from GFP-VAMP7–labeled melanosomes was manually counted over all 300 frames of an image sequence.
Statistical analysis
Statistical significance was determined by the unpaired two-tailed Student’s t test. All values are indicated as ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.005; and ****, P < 0.0001.
Online supplemental material
Fig. S1 provides supporting evidence that VAMP7 resides in melanosomes and that it is trapped in early endosomes in a second BLOC-1–deficient model. Fig. S2 shows a still image of the entire cell from a frame of an image sequence of GFP-VAMP7 or TYRP1-GFP and mCh-STX13 in WT cells, an inset of which is shown in Fig. 4 and Videos 1 and 2; a corresponding image sequence of GFP-VAMP7 and mCh-STX13 in BLOC-1–deficient cells as a control, also seen in Video 5; quantification of GFP-VAMP7 and mCh-STX13 tubule length and stability in WT melan-Ink4a melanocytes; still images of the entire cell from the first frame of image sequences of insets shown in Fig. 5, and Videos 6 and 7; and an image sequence in which a GFP-VAMP7–labeled tubule emerges from a melanosome labeled by mRFP-OCA2, supporting Fig. 5 and Video 8. Fig. S3 shows the entire cell from the first frame of image sequences, insets of which are shown in Fig. 6 and Videos 9 and 11, and shows image sequences derived from Video 10, in which a tubule marked by VARP-GFP, but not TYRP1-mRFP, exits a melanosome. Fig. S4 shows representative localization of the lysosomal protein LAMP2 and the melanosomal protein TYRP1 in WT and BLOC-3–deficient le:HPS1 and images from HPS4-deficient le melanocytes mock-rescued by expression of the BLOC-3 subunit HPS1 (le:HPS1) in which neither RAB38-GFP nor VARP-GFP localization is restored to melanosomes, supporting Fig. 9. Fig. S5 provides supporting evidence that VARP and RAB38, but not VAMP7, are mislocalized and depleted from melanosomes in a second BLOC-3-deficient cell model. Video 1 shows that GFP-VAMP7 and mCh-STX13 label separate tubule populations in WT melanocytes. Video 2 shows that TYRP1-GFP is undetectable in anterograde mCh-STX13 tubules in WT melanocytes. Video 3 shows that GFP-VAMP7 is detected in mCh-STX13 tubules in transiently rescued melan-pa melanocytes with restored BLOC-1 function. Video 4 shows that TYRP1-GFP is detected in mCh-STX13 tubules in transiently rescued melan-pa melanocytes with restored BLOC-1 function. Video 5 shows that GFP-VAMP7 and mCh-STX13 are retained in enlarged endosomes and that mCh-STX13 tubules are dramatically reduced in in BLOC-1–deficient melanocytes. Video 6 shows that GFP-VAMP7–labeled tubules exit pigmented melanosomes. Video 7 shows that TYRP1-mRFP is undetectable in GFP-VAMP7–labeled tubules that emerge from melanosomes labeled by GFP-VAMP7 and TYRP1-mRFP. Video 8 shows that mRFP-OCA2 is undetectable in GFP-VAMP7-labeled tubules that emerge from melanosomes labeled by GFP-VAMP7 and mRFP-OCA2. Video 9 shows that mCh-VAMP7 tubules are also labeled by VARP-GFP. Video 10 shows that TYRP1-mRFP is undetectable in VARP-GFP–labeled tubules that emerge from TYRP1-mRFP–labeled melanosomes. Video 11 shows that mRFP-OCA2 is undetectable in VARP-GFP–labeled tubules that emerge from mRFP-OCA2–labeled melanosomes. Video 12 shows that VARP-GFP labels tubules that originate from STX13-labeled endosomes but that these tubules are distinct from those that are labeled by mCh-STX13 and destined for melanosomes. Video 13 shows that GFP-RAB38 is present on mCh-VAMP7–containing tubules that emerge from melanosomes. Video 14 shows examples of regions of interest for quantification of GFP-VAMP7 tubules departing melanosomes in WT, le:HPS1, and le:HPS4 melanocytes for analyses shown in Fig. 10 d.
Acknowledgments
We thank A. Stout (Penn Cell and Developmental Biology Microscopy Core) and J. Burkhardt for use of spinning-disc microscopes; the Nikon Imaging Center at Institut Curie-Centre National de la Recherche Scientifique and The BioImaging Cell and Tissue Core Facility (PICT-IBiSA), supported by the CelTisPhyBio Labex (ANR-10-LBX-0038) and IDEX Paris Sciences et Lettres Research University (ANR-10-IDEX-0001-02); J. Bonifacino, A. Hume, A. Peden, and P. Roche for gifts of reagents; and A. Mantegazza and D. Harper for technical help.
This work was supported by grants from the National Institutes of Health, National Eye Institute (R01 EY015625, to M.S. Marks and G. Raposo), National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR048155, to M.S. Marks, and F32 AR062476, to M.K. Dennis), National Institute of General Medical Sciences (R01 GM108807, to M.S. Marks); Fondation pour la Recherche Médicale (to T. Galli); the UK Medical Research Council (G0900113, to J.P. Luzio); and the Wellcome Trust (108429, to E.V. Sviderskaya and D.C. Bennett). This work was also supported by a Canadian Institutes of Health Research Fellowship (to G.G. Hesketh) and a Fondation pour la Recherche Médicale grant from Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Curie, and Fondation pour la Recherche Médicale (DEQ20140329491 Team label, to G. Raposo).
The authors declare no competing financial interests.